AKYA AKOYA BIOSCIENCES INC

Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences

Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences

MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to . It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at .

Akoya also announced that management will be presenting or doing fireside chats at two upcoming investor conferences.

  • Canaccord Genuity 44th Annual Growth Conference
    • Tuesday, August 13 at 2:30 PM ET
  • Morgan Stanley 22nd Annual Global Healthcare Conference
    • Friday, September 6 at 1:05 PM ET

A live and archived webcast of the events will be available on the “Investors” section of the Akoya website at .

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit .

Investor Contact:

Priyam Shah

Media Contact:

Christine Quern



EN
15/07/2024

Underlying

AKYAAKOYA BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AKOYA BIOSCIENCES INC

 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Reports Second Quarter 2024 Financial Results

Akoya Biosciences Reports Second Quarter 2024 Financial Results MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024. “Our second-quarter revenue showed a strong rebound with 26% sequential top-line growth and a stable year-over-year performance,” said Brian McKelligon, CEO of Akoya Biosciences. “We believe that Akoya’s platforms are poised to lead the spatial biology market from discovery to diagnostics, while we also position the company to achi...

August 5, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences to Report Second Quarter 2024 Financial Results on A...

Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to . It is recommended...

July 15, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Reports First Quarter 2024 Financial Results

Akoya Biosciences Reports First Quarter 2024 Financial Results MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. Business Highlights Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.Akoya the establishment of a new Manufacturing Center of Excellence in Marlborough, Massachusetts to scal...

May 13, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to En...

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of lab...

May 9, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Opens Operations and Manufacturing Center of Excelle...

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms. “Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our ability to un...

May 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch